This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hoelzer D, Gokbuget N, Ottmann O, Pui CH, Relling MV, Appelbaum FR et al. Acute lymphoblastic leukemia. Am Soc Haematol Educat Prog 2002, 162–192.
Hale G, Bright S, Chumbley G, Hoang T, Metcalf D, Munro AJ et al. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood 1983; 62: 873–882.
Zhang Z, Zhang M, Goldman CK, Ravetch JV, Waldmann TA . Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H. Cancer Res 2003; 63: 6453–6457.
Keating MJ, Cazin B, Coutre S, Birhiray R, Kovacsovics T, Langer W et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Onc 2002; 20: 205–213.
Dearden CE, Matutes E, Cazin B, Tjonnfjord GE, Parreira A, Nomdedeu B et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood 2001; 98: 1721–1726.
Boissel N, Auclerc MF, Lheritier V, Perel Y, Thomas X, Leblanc T et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 2003; 21: 760–761.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Laporte, J., Isnard, F., Garderet, L. et al. Remission of adult acute lymphocytic leukaemia with Alemtuzumab. Leukemia 18, 1557–1558 (2004). https://doi.org/10.1038/sj.leu.2403422
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403422
This article is cited by
-
Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: a monocentric study of 44 cases
Leukemia (2009)
-
Application of immunotherapy in pediatric leukemia
Current Hematologic Malignancy Reports (2009)
-
Combination of chemotherapy and gemtuzumab ozogamicin in adult Philadelphia positive acute lymphoblastic leukemia patient harboring CD33 expression
International Journal of Hematology (2008)
-
New therapeutic strategies for the treatment of acute lymphoblastic leukaemia
Nature Reviews Drug Discovery (2007)
-
Alemtuzumab in the treatment of relapsed acute lymphoid leukaemia
Leukemia (2005)